Biotech Values

[DewDiligence]

AZN will conduct a 21,000-patient Brilinta trial to assess long-term MACE prevention following a heart attack:

http://www.bloomberg.com/news/2010-10-01/astrazeneca-to-start-long-term-brilinta-heart-attack-study.html

If successful, this study will strongly differentiate Brilinta from (generic) Plavix, which failed to show a benefit in a similar study a few years ago.